First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.

Autor:	Yamamoto S; Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan., Narui K; Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan; nr1@gc5.so-net.ne.jp., Ishikawa T; Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan., Adachi S; Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan., Shimada K; Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan., Shimizu D; Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan., Yamada A; Yokohama City University Graduate School of Medicine, Department of Gastroenterological Surgery, Yokohama, Japan., Sugae S; Yokohama City University Graduate School of Medicine, Department of Gastroenterological Surgery, Yokohama, Japan., Tanabe M; Yokohama City University Medical Center, Department of Pathology, Yokohama, Japan., Oba M; Yokohama City University Medical Center, Department of Biostatics and Epidemiology, Yokohama, Japan., Morita S; Kyoto University Graduate School of Medicine, Department of Biomedical Statistics and Bioinformatics, Kyoto, Japan., Doi T; Shonan Kinen Hospital, Breast Center, Kamakura, Japan., Hasegawa S; Saiseikai Yokohama-shi Nanbu Hospital, Department of Surgery, Yokohama, Japan., Morita T; Yokosuka Kyosai Hospital, Department of Surgery, Yokosuka, Japan., Kito A; Yokohama Municipal Citizen's Hospital, Department of Breast Surgery, Yokohama, Japan., Chishima T; Yokohama Rosai Hospital, Department of Breast Surgery, Yokohama, Japan., Ichikawa Y; Yokohama City University Graduate School of Medicine, Department of Clinical Oncology, Yokohama, Japan., Endo I; Yokohama City University Graduate School of Medicine, Department of Gastroenterological Surgery, Yokohama, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2021 Mar; Vol. 41 (3), pp. 1671-1676.
DOI:	10.21873/anticanres.14930
Abstrakt:	Background/aim: This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of physician's choice (TPC). Patients and Methods: We enrolled 96 patients into the first-line gemcitabine group (n=47) or other treatment of physician's choice (TPC) group (n=49) from May 2010 to April 2013. HRQoL was evaluated every 4 weeks. Results: There was no significant difference in the median time to treatment failure (5.3 vs. 4.6 months, hazard ratio=0.87, p=0.546) and the incidence rates of grade 3/4 haematological toxicity (10.6% vs. 8.1%, p=0.677) and grade 3/4 non-haematological toxicity (4.2% vs. 8.1%, p=0.429) between the gemcitabine and TPC groups. Changes in HRQoL from baseline to 12 weeks were not significantly different. Conclusion: Gemcitabine achieves similar efficacy and HRQoL benefit to other chemotherapy and can be used as first-line treatment for MBC. (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu